22:52:35 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-07 Kvartalsrapport 2024-Q3
2024-08-08 Kvartalsrapport 2024-Q2
2024-05-13 Ordinarie utdelning OPTOMED 0.00 EUR
2024-05-10 Årsstämma 2024
2024-05-07 Kvartalsrapport 2024-Q1
2024-02-15 Bokslutskommuniké 2023
2023-11-03 Kvartalsrapport 2023-Q3
2023-08-04 Kvartalsrapport 2023-Q2
2023-05-11 Ordinarie utdelning OPTOMED 0.00 EUR
2023-05-10 Årsstämma 2023
2023-05-05 Kvartalsrapport 2023-Q1
2023-02-17 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-09-06 Extra Bolagsstämma 2022
2022-08-04 Kvartalsrapport 2022-Q2
2022-05-11 Ordinarie utdelning OPTOMED 0.00 EUR
2022-05-10 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-08-05 Kvartalsrapport 2021-Q2
2021-05-06 Kvartalsrapport 2021-Q1
2021-04-29 Ordinarie utdelning OPTOMED 0.00 EUR
2021-04-28 Årsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-25 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-06-12 Ordinarie utdelning OPTOMED 0.00 EUR
2020-06-11 Årsstämma 2020
2020-05-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019

Beskrivning

LandFinland
ListaSmall Cap Helsinki
SektorHälsovård
IndustriMedicinteknik
Optomed är verksamt inom medicinteknik. Bolaget bedriver forskning och utveckling av specialiserade ögonkameror. Utveckling sker av både hård- och mjukvara som vidaresäljs under olika varumärken. Verksamhet innehas på global nivå, med störst närvaro inom den nordiska marknaden. Kunderna består av forskningsinstitut samt sjukhus. Huvudkontoret ligger i Oulu.
2023-11-02 09:00:00

Optomed PlcStock Exchange Release2 November 2023 at 10.00, Helsinki

Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

Optomed Plc ("Optomed" or the "Company") has received a notification in accordance with the Chapter 9, Section 5 of the Finnish Securities Markets Act (as amended, the "SMA") from Universal-Investment-Gesellschaft mit beschränkter Haftung ("Notifier"). According to the notification, the total holdings in Optomed shares and votes held by Notifier is 4.98 per cent of all of the registered shares in Optomed on 31 October 2023.

The total number of the Company's registered shares amounts to 18,130,397 shares. Each share entitles to one vote.

The total position of Notifier subject to the notification:

+----------------+----------+------------------+-----+----------------------+
| |% of |% of shares and |Total|Total number of shares|
| |shares and|voting rights |of |and voting rights of |
| |voting |through financial |both |issuer |
| |rights |instruments (total|in % | |
| |(total |of B) |(A+B)| |
| |of A) | | | |
+----------------+----------+------------------+-----+----------------------+
|Resulting |4.98 % |- |4.98 |18130 397 |
|situation on the| | |% | |
|date on | | | | |
|which threshold | | | | |
|was crossed or | | | | |
|reached | | | | |
+----------------+----------+------------------+-----+----------------------+
|Position of |7.49 % |- |7.49 | |
|previous | | |% | |
|notification | | | | |
|(if applicable) | | | | |
+----------------+----------+------------------+-----+----------------------+

Notified details of the resulting situation on the date on which the threshold was crossed or reached:

A: Shares and voting rights

+------------+-----------------+----------------+-----------------+-----------+
|Class/type |Number of shares and voting rights|% of shares and voting rights|
|of shares | | |
| | | |
|ISIN code | | |
+------------+-----------------+----------------+-----------------+-----------+
|Direct |Indirect |Direct |Indirect |
|(SMA 9:5) |(SMA 9:6 and 9:7)|(SMA 9:5) |(SMA 9:6 and 9:7)|
+------------+-----------------+----------------+-----------------+-----------+
|FI4000410881|- |903202 | |4.98 % |
+------------+-----------------+----------------+-----------------+-----------+
|SUBTOTAL A |903 202 |4.98 % |
+------------+-----------------+----------------+-----------------+-----------+

Information in relation to the person subject to the notification obligation as contained in the notification

The complete chain of controlled undertakings through which the shares, voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:

+--------------------+-----------+-----------------------------+------+
|Name |% of shares|% of shares and voting rights|Total |
| |and voting |through financial instruments|of |
| |rights | |both |
+--------------------+-----------+-----------------------------+------+
|Universal-Investment|- |- |- |
|-Gesellschaft mit | | | |
|beschränkter Haftung| | | |
+--------------------+-----------+-----------------------------+------+
|Universal-Investment|4.98 % |- |4.98 %|
|-Luxembourg S.A | | | |
+--------------------+-----------+-----------------------------+------+
| |- |- |- |
+--------------------+-----------+-----------------------------+------+

Further enquiries

Sakari Knuutti, CFO, Optomed Plc, sakari.knuutti@optomed.com,+358(0)50562 4077.

Optomed in Brief

Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye diseases, such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries.

www.optomed.com